Nov 22, 2021 - Dec 02, 2021 / NTS GMT
Ted Tenthoff - Piper Sandler - Analyst
Hello, my name is Ted Tenthoff, and I'm a senior biotechnology analyst at Piper Sandler. Thank you for joining us for this year's virtual healthcare conference. Onconova is developing rigosertib for KRAS+ non-small cell lung cancer and also multi-kinase inhibitor narazaciclib for solid tumors. Here to present for the Company is President and CEO, Dr. Steven Fruchtman. Steve, take it away.
Steven Fruchtman - Onconova Therapeutics, Inc. - President and CEO
Thank you so much, and thank you to Piper Sandler for the opportunity to present what we believe is a very exciting scientific platform. As introduced, my name is Steve Fruchtman. I'm the President and CEO of Onconova, and by training, I'm a hematologist/oncologist, academic career at Mount Sinai Hospital in New York. I've been in the industry for about 15 years, initially at Ortho Biotech, Novartis, and then a series of small biotech companies. I've been fortunate enough to get about 8 to 10 drugs in hematology/oncology through the FDA and hope to do the same
Onconova Therapeutics Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
Feb 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers